|
1
|
Cannistra SA: Cancer of the ovary. N Engl
J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kindelberger DW, Lee Y, Miron A, Hirsch
MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW,
Birch C, et al: Intraepithelial carcinoma of the fimbria and pelvic
serous carcinoma: Evidence for a causal relationship. Am J Surg
Pathol. 31:161–169. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yoshida S, Furukawa N, Haruta S, Tanase Y,
Kanayama S, Noguchi T, Sakata M, Yamada Y, Oi H and Kobayashi H:
Expression profiles of genes involved in poor prognosis of
epithelial ovarian carcinoma: A review. Int J Gynecol Cancer.
19:992–997. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Saad AF, Hu W and Sood AK:
Microenvironment and pathogenesis of epithelial ovarian cancer.
Horm Cancer. 1:277–290. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lengyel E: Ovarian cancer development and
metastasis. Am J Pathol. 177:1053–1064. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cormio G, Rossi C, Cazzolla A, Resta L,
Loverro G, Greco P and Selvaggi L: Distant metastases in ovarian
carcinoma. Int J Gynecol Cancer. 13:125–129. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Naora H and Montell DJ: Ovarian cancer
metastasis: Integrating insights from disparate model organisms.
Nat Rev Cancer. 5:355–366. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Weiswald LB, Bellet D and Dangles-Marie V:
Spherical cancer models in tumor biology. Neoplasia. 17:1–15. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yan XD, Li M, Yuan Y, Mao N and Pan LY:
Biological comparison of ovarian cancer resistant cell lines to
cisplatin and Taxol by two different administrations. Oncol Rep.
17:1163–1169. 2007.PubMed/NCBI
|
|
10
|
Soriţău O, Tomuleasa CI, Páll E, Virág P,
Fischer-Fodor E, Foris V, Barbos O, Tatomir C, Kacsó G and Irimie
A: Enhanced chemoresistance and tumor sphere formation as a
laboratory model for peritoneal micrometastasis in epithelial
ovarian cancer. Rom J Morphol Embryol. 51:259–264. 2010.PubMed/NCBI
|
|
11
|
Xu F, Celli J, Rizvi I, Moon S, Hasan T
and Demirci U: A three-dimensional in vitro ovarian cancer
coculture model using a high-throughput cell patterning platform.
Biotechnol J. 6:204–212. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu G, Yin F, Wu H, Hu X, Zheng L and Zhao
J: In vitro ovarian cancer model based on three-dimensional agarose
hydrogel. J Tissue Eng. 5:2041731413520438. 2014.doi:
10.1177/2041731413520438. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hannon GJ: RNA interference. Nature.
418:244–251. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lehrbach NJ and Miska EA: Regulation of
pre-miRNA Processing. Adv Exp Med Biol. 700:67–75. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lenkala D, Gamazon ER, LaCroix B, Im HK
and Huang RS: MicroRNA biogenesis and cellular proliferation.
Transl Res. 166:145–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Didiano D and Hobert O: Molecular
architecture of a miRNA-regulated 3′ UTR. RNA. 14:1297–1317. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Peterson SM, Thompson JA, Ufkin ML,
Sathyanarayana P, Liaw L and Congdon CB: Common features of
microRNA target prediction tools. Front Genet. 5:232014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
O'Connell RM, Rao DS, Chaudhuri AA and
Baltimore D: Physiological and pathological roles for microRNAs in
the immune system. Nat Rev Immunol. 10:111–122. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Macfarlane LA and Murphy PR: MicroRNA:
Biogenesis, function and role in cancer. Curr Genomics. 11:537–561.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kutanzi KR, Yurchenko OV, Beland FA,
Checkhun VF and Pogribny IP: MicroRNA-mediated drug resistance in
breast cancer. Clin Epigenetics. 2:171–185. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li SD, Zhang JR, Wang YQ and Wan XP: The
role of microRNAs in ovarian cancer initiation and progression. J
Cell Mol Med. 14:2240–2249. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Boyerinas B, Park SM, Hau A, Murmann AE
and Peter ME: The role of let-7 in cell differentiation and cancer.
Endocr Relat Cancer. 17:F19–F36. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu D, Wolf JK, Scanlon M, Price JE and
Hung MC: Enhanced c-erbB-2/neu expression in human ovarian cancer
cells correlates with more severe malignancy that can be suppressed
by E1A. Cancer Res. 53:891–898. 1993.PubMed/NCBI
|
|
24
|
Zhao Y, Shen S, Guo J, Chen H, Greenblatt
DY, Kleeff J, Liao Q, Chen G, Friess H and Leung PS:
Mitogen-activated protein kinases and chemoresistance in pancreatic
cancer cells. J Surg Res. 136:325–335. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung
Y, Komarov AP, Keyomarsi K, Yarden Y and Seger R: Taxol-induced
apoptosis depends on MAP kinase pathways (ERK and p38) and is
independent of p53. Oncogene. 20:147–155. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Park SH, Seong MA and Lee HY: p38
MAPK-induced MDM2 degradation confers paclitaxel resistance through
p53-mediated regulation of EGFR in human lung cancer cells.
Oncotarget. 7:8184–8899. 2016.PubMed/NCBI
|
|
27
|
Okano J and Rustgi AK: Paclitaxel induces
prolonged activation of the Ras/MEK/ERK pathway independently of
activating the programmed cell death machinery. J Biol Chem.
276:19555–19564. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ribeiro JR, Schorl C, Yano N, Romano N,
Kim KK, Singh RK and Moore RG: HE4 promotes collateral resistance
to cisplatin and paclitaxel in ovarian cancer cells. J Ovarian Res.
9:282016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
McGrail DJ, Khambhati NN, Qi MX, Patel KS,
Ravikumar N, Brandenburg CP and Dawson MR: Alterations in ovarian
cancer cell adhesion drive taxol resistance by increasing
microtubule dynamics in a FAK-dependent manner. Sci Rep.
5:95292015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang N, Zhang H, Yao Q, Wang Y, Dai S and
Yang X: TGFBI promoter hypermethylation correlating with paclitaxel
chemoresistance in ovarian cancer. J Exp Clin Cancer Res. 31:62012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gallant ND, Michael KE and García AJ: Cell
adhesion strengthening: Contributions of adhesive area, integrin
binding, and focal adhesion assembly. Mol Biol Cell. 16:4329–4340.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jin H and Varner J: Integrins: Roles in
cancer development and as treatment targets. Br J Cancer.
90:561–565. 2004. View Article : Google Scholar : PubMed/NCBI
|
